Clinical Trials

Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study

Novartis announced that its Cosentyx (secukinumab) has achieved its primary and key secondary endpoint in the Maximise study of psoriatic arthritis (PsA).

Dr. Reddy’s announces positive topline results from phase 2b study of PPC-06 in moderate to severe plaque psoriasis

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

ProtoKinetix achieves primary objective safety at midpoint of clinical trial

ProtoKinetix, announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type-1 diabetes.

Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial

AstraZeneca’s blood cancer drug Calquence (acalabrutinib) in combination with obinutuzumab met the primary endpoint at interim analysis in the phase 3 ELEVATE-TN trial in previously-untreated chronic lymphocytic leukaemia (CLL).

Novartis says iscalimab may prolong durability of transplanted kidneys

Novartis has announced new early stage histology data in kidney transplantation, suggesting that with investigational compound iscalimab (CFZ533) it may be possible to prolong the durability of transplanted kidneys as well as to potentially improve long-term outcomes for kidney transplant patients.

Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease

Goldfinch Bio has initiated dosing in a Phase 1 clinical trial evaluating GFB-887, its subtype-selective, small molecule TRPC5 inhibitor, as a potential treatment for kidney diseases associated with proteinuria and progressive renal dysfunction including focal segmental glomerulosclerosis (FSGS), treatment-resistant minimal change disease (TR-MCD) and diabetic nephropathy (DN).

Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL

Roche and AbbVie’s chemotherapy-free combination therapy of Venclexta/Venclyxto (venetoclax) and Gazyva/Gazyvaro (obinutuzumab) succeeded in a phase 3 trial in previously untreated chronic lymphocytic leukaemia (CLL).

CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC

CStone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development in China of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC).

LYNPARZA delivers 72% ORR in phase 3 SOLO3 trial in advanced ovarian cancer

AstraZeneca and Merck presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with germline BRCA1/2-mutated (gBRCAm) advanced ovarian cancer, who have received two more prior lines of chemotherapy.